JJ
Merck and J&J invest in Chinese manufacturing
November 18, 2013Manufacturing and Production J&J, JJ, Merck, manufacturing
Merck KGaA and Johnson & Johnson have both announced new manufacturing projects in China, suggesting investigations into corruption by the …
J&J ‘to pay out $4 billion’ in fresh legal case
November 14, 2013Sales and Marketing J&J, JJ, Risperdal, fines, hip replacement
Johnson & Johnson is set to pay up to $4 billion to settle thousands of legal cases related to patients …
J&J hit with $2.2 billion fine
November 5, 2013Sales and Marketing J&J, JJ, Janssen, Risperdal, antipsychotic, fine
Johnson & Johnson has admitted promoting its big-selling antipsychotic drug Risperdal off-label, costing the firm $2.2 billion in fines. The …
Former FDA commissioner joins J&J
October 16, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, J&J, JJ
Johnson & Johnson has announced that ex-FDA commissioner Mark McClellan has been appointed to its Board of directors. Dr McClellan …
Johnson & Johnson posts strong Q3 results
October 16, 2013Sales and Marketing J&J, JJ, Q3, Velcade, results
Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …
J&J partners with European biotech firms
October 4, 2013Research and Development, Sales and Marketing J&J, JJ, effimune, life sciences, merus
The London Johnson & Johnson Innovation Centre has teamed up with several biotech partners from the European region. Announced at …
J&J’s prescription drugs unit hit by recall
September 17, 2013Manufacturing and Production J&J, JJ, Risperdal, Tylenol, recalls
J&J’s manufacturing recovery hits a hurdle
September 10, 2013Manufacturing and Production API, J&J, JJ, McNeil, Motrin, recall
Johnson & Johnson’s path back to regulatory compliance in its manufacturing operations has hit another snag after the firm was …
J&J says revived OTC brands are ‘winning the hearts of consumers’
July 19, 2013Manufacturing and Production, Sales and Marketing Control, FDA, GDP, J&J, JJ, OTC
Johnson & Johnson doesn’t usually provide specific financials for its over-the-counter pharmaceuticals business, but did so for the first time …
J&J sees Q2 sales rise
July 17, 2013Sales and Marketing Elan, J&J, JJ, Q2, Synthes, sales
Johnson & Johnson saw overall sales rise 8.5% year-on-year in the second quarter of 2013, with the US healthcare group …
Next generation digital firms for Europe wanted
July 15, 2013Medical Communications, Sales and Marketing J&J, JJ, digital, innovation
Digital health start-ups from across Europe are being called on to form a part of Johnson & Johnson Innovation’s inaugural …
J&J opens office at Stevenage Bioscience Catalyst
June 21, 2013Manufacturing and Production, Research and Development J&J, JJ, bioscience, catalyst
Johnson & Johnson Innovation has establishment a partnering office at Stevenage Bioscience Catalyst to support emerging entrepreneurs and biotech firms …
J&J to pay up to $1 billion in Aragon deal
June 18, 2013Research and Development, Sales and Marketing Aragon, J&J, JJ, Zytiga
Johnson & Johnson could pay as much as $1 billion to buy prostate cancer specialist Aragon Pharmaceuticals. The acquisition includes …
J&J recalls 32 million contraceptive packs
June 5, 2013Manufacturing and Production Cilest, J&J, JJ, recall
Johnson & Johnson has announced a 43-country recall of its oral contraceptive Cilest and suspended production of the drug because …
South Korea eyeing criminal charges over J&J plant failures
May 17, 2013Manufacturing and Production J&J, JJ, Janssen, Korea, MFDS
The chief executive of Johnson & Johnson’s South Korean subsidiary could be facing criminal charges over quality lapses at a …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
